CDKL5 Deficiency Disorder (CDD)
Also known as: CDKL5 Deficiency Disorder / CDKL5 Disorder / Cyclin-Dependent Kinase-Like 5 Deficiency Disorder / Cyclin-dependent kinase-like 5 deficiency (disorder)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB05087 | Ganaxolone | A neuroactive steroid GABA-A receptor modulator used for the treatment of seizures associated with CDKL5 deficiency disorder (CDD). |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB05087 | Ganaxolone | GABA(A) Receptor | target |
| DB05087 | Ganaxolone | Cytochrome P450 3A4 | enzyme |
| DB05087 | Ganaxolone | Cytochrome P450 3A5 | enzyme |
| DB05087 | Ganaxolone | Cytochrome P450 2B6 | enzyme |
| DB05087 | Ganaxolone | Cytochrome P450 2C19 | enzyme |
| DB05087 | Ganaxolone | Cytochrome P450 2D6 | enzyme |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB00574 | Fenfluramine | 3 | Recruiting | 1 |
| DB05087 | Ganaxolone | 3 | Completed | 1 |
| DB05087 | Ganaxolone | 3 | Not Yet Recruiting | 1 |
| DB05087 | Ganaxolone | Not Available | No Longer Available | 1 |